Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

BACKGROUND: The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented. METHODS: Remission and resp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gastroenterol
Autors principals: Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Hibi, Toshifumi, Nakamura, Shiro, Lazar, Andreas, Robinson, Anne Martin, Skup, Martha, Mostafa, Nael Mohamed, Huang, Bidan, Thakkar, Roopal, Watanabe, Mamoru
Format: Artigo
Idioma:Inglês
Publicat: Springer Japan 2017
Matèries:
Original Article—Alimentary Tract
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569655/
https://ncbi.nlm.nih.gov/pubmed/28321512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-017-1325-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars